Amendment: SEC Form SC 13G/A filed by Alvotech

$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $ALVO alert in real time by email
SC 13G/A 1 tm2427411d1_sc13ga.htm SC 13G/A

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

AMENDMENT NO. 1 TO SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

Alvotech

(Name of Issuer)

 

 

Ordinary Shares, with nominal value of $0.01 per share

(Title of Class of Securities)

 

L01800108

(CUSIP Number)

 

September 30, 2024

(Date of Event, which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨       Rule 13d-1(b)

x      Rule 13d-1(c)

¨       Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information, which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act out shall be subject to all other provisions of the Act, (however, see the Notes).

 

 

 

 

 

 

CUSIP No. L01800108

 

  1. Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
YA II PN, Ltd.
(98-0615462)
 
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
     
  3. SEC Use Only
     
  4. Citizenship or Place of Organization:  Cayman Islands
     

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power: 0
     
     
6 Shared Voting Power: 0
     
     
7. Sole Dispositive Power: 0
     
     
8. Shared Dispositive Power: 0
     

  9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
     
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
     
  11. Percentage of Class Represented by Amount in Row (9):        0%
     
  12. Type of Reporting Person (See Instructions):     OO

 

 

 

 

CUSIP No. L01800108

 

  1. Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
YA Global Investments II (U.S.), LP
     
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
     
  3. SEC Use Only
     
  4. Citizenship or Place of Organization:  Delaware
     

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power: 0
     
     
6 Shared Voting Power: 0
     
     
7. Sole Dispositive Power: 0
     
     
8. Shared Dispositive Power: 0
     

  9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
     
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
     
  11. Percentage of Class Represented by Amount in Row (9):         0%
     
  12. Type of Reporting Person (See Instructions):     OO

 

 

 

 

CUSIP No. L01800108

 

  1. Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
Yorkville Advisors Global, LP
   
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
     
  3. SEC Use Only
     
  4. Citizenship or Place of Organization:  Delaware
     

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power: 0
     
     
6 Shared Voting Power: 0
     
     
7. Sole Dispositive Power: 0
     
     
8. Shared Dispositive Power: 0
     

  9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
     
  10. Check if the Aggregate Amount in Row (9)  Excludes Certain Shares (See Instructions) ¨
     
  11. Percentage of Class Represented by Amount in Row (9):         0%
     
  12. Type of Reporting Person (See Instructions):     OO

 

 

 

 

CUSIP No. L01800108

 

  1. Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
Yorkville Advisors Global II, LLC
     
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
     
  3. SEC Use Only
     
  4. Citizenship or Place of Organization:  Delaware
     

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power: 0
     
     
6 Shared Voting Power: 0
     
     
7. Sole Dispositive Power: 0
     
     
8. Shared Dispositive Power: 0
     

  9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
     
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
     
  11. Percentage of Class Represented by Amount in Row (9):         0%
     
  12. Type of Reporting Person (See Instructions):     OO

 

 

 

 

CUSIP No. L01800108

 

  1. Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
YAII GP, LP
     
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
     
  3. SEC Use Only
     
  4. Citizenship or Place of Organization:  Delaware
     

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power: 0
     
     
6 Shared Voting Power: 0
     
     
7. Sole Dispositive Power: 0
     
     
8. Shared Dispositive Power: 0
     

  9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
     
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
     
  11. Percentage of Class Represented by Amount in Row (9):         0%
     
  12. Type of Reporting Person (See Instructions):     OO

 

 

 

 

CUSIP No. L01800108

 

  1. Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
YAII GP II, LLC
     
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
     
  3. SEC Use Only
     
  4. Citizenship or Place of Organization:  Delaware
     

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power: 0
     
     
6 Shared Voting Power: 0
     
     
7. Sole Dispositive Power: 0
     
     
8. Shared Dispositive Power: 0
     

  9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
     
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
     
  11. Percentage of Class Represented by Amount in Row (9):         0%
     
  12. Type of Reporting Person (See Instructions):     OO

 

 

 

 

CUSIP No. L01800108

 

  1. Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
Mark Angelo
     
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
     
  3. SEC Use Only
     
  4. Citizenship or Place of Organization:  United States
     

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power: 0
     
     
6 Shared Voting Power: 0
     
     
7. Sole Dispositive Power: 0
     
     
8. Shared Dispositive Power: 0
     

  9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
     
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
     
  11. Percentage of Class Represented by Amount in Row (9):         0%
     
  12. Type of Reporting Person (See Instructions):     OO

 

 

 

 

CUSIP No. L01800108

 

  1. Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
SC-Sigma Global Partners, LP
84-5173620
     
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
     
  3. SEC Use Only
     
  4. Citizenship or Place of Organization:  Delaware
     

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power: 0
     
     
6 Shared Voting Power: 0
     
     
7. Sole Dispositive Power: 0
     
     
8. Shared Dispositive Power: 0
     

  9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
     
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
     
  11. Percentage of Class Represented by Amount in Row (9):         0%
     
  12. Type of Reporting Person (See Instructions):     OO

 

 

 

 

This Amendment No. 1 is being filed by YA II PN, Ltd., YA Global Investments II (U.S.), Ltd., Yorkville Advisors Global, LP, Yorkville Advisors Global II, LLC, YA II GP, LP, YAII GP II, LLC and SC-Sigma Global Partners, LP (collectively, the “Reporting Persons”) and amends, supplements and supersedes, the initial Schedule 13G filed jointly by the Reporting Persons on February 14, 2023. This Amendment No. 1 is the final amendment to the Schedule 13G and constitutes an exit filing for the Reporting Persons.

 

Item 1.

 

  (a) Name of Issuer:

 

Alvotech

 

  (b) Address of Issuer’s Principal Executive Offices:

 

9, Rue de Bitbourg

Luxembourg, Luxembourg L-1273

 

Item 2. Identity and Background.

 

  (a) Name of Person Filing:

 

YA II PN, Ltd.

 

  (b) Address of Principal Executive Office or, if none, Residence of Reporting Persons:

 

1012 Springfield Ave.

Mountainside, NJ 07092

 

  (c) Citizenship:

 

Cayman Islands

 

  (d) Title of Class of Securities:

 

Ordinary Shares, with nominal value of $0.01 per share

 

  (e) CUSIP Number:

 

L01800108

 

Item 3. If the statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is:

 

(a) ¨  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b) ¨  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c) ¨  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d) ¨  Investment company registered under section 8 of the Investment Company Act of 1940 (15 of the Act (15 U.S.C. 78o);
(e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h) ¨  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) ¨  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); or
(k) x  Group, in accordance with 240.13d(b)(1)(ii)(K).

 

 

 

 

Item 4. Ownership

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

 

  (a) Amount beneficially owned: 0

 

  (b) Percentage of Class: 0%

 

  (c) Number of shares as to which the person has:

 

  (i) Sole Power to vote or to direct the vote: 0

 

  (ii) Shared power to vote or to direct the vote: 0

 

  (iii) Sole power to dispose or to direct the disposition: 0

 

  (iv) Shared power to dispose or to direct the disposition: 0

 

Item 5. Ownership of Five Percent or Less of a Class:

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

 

Item 6. Ownership of more than five percent on Behalf of Another Person.

 

Not Applicable

 

 

 

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

Not Applicable

 

Item 8. Identification and Classification of Member Group

 

YA II PN, Ltd. (“YA II”) is beneficially owned by YA Global Investments II (U.S.), LP (the “YA Feeder”). Yorkville Advisors Global, LP (the “YA Advisor”) is the investment manager to YA II. Yorkville Advisors Global II, LLC (the “YA Advisor GP”) is the general partner to the YA Advisor. YAII GP, LP (the “YA GP”) is the general partner to the YA Feeder. YAII GP II, LLC (the “Yorkville GP”) is the general partner to the YA GP. Mark Angelo makes the investment decisions on behalf of YA II. Accordingly, each of YA II, YA Feeder, the YA Advisor, the YA Advisor GP, the YA GP, the Yorkville GP and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of Class A Shares.

 

YAII GP, LP is the general partner of SC-Sigma Global Partners, LP (“SC-Sigma”), which is an investor in YA II. YAII GP II, LLC is the general partner of YAII GP, LP. The YA Advisor is the investment manager to SC-Sigma. Accordingly, SC-Sigma, the YA GP, the Yorkville GP, the YA Advisor, and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of shares of Class A Shares. 

 

For purposes of this filing, each of the reporting persons is deemed an affiliate of each other reporting person.

 

Item 9. Notice of Dissolution of Group

 

Not Applicable

 

Item 10. Certification

 

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

 

Additional Information:

 

Each Reporting Person disclaims beneficial ownership of any securities beneficially owned by each other Reporting Person, and its report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of these securities for the purpose of Section 16 or for any other purpose.

 

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement in true, complete and correct.

 

  REPORTING PERSON:  
     
Dated: November 6, 2024  
 
  REPORTING PERSON:
 
YA II PN, Ltd.  
   
By: /s/ Robert Munro  
  Robert Munro  
  Chief Compliance Officer  
   
YA Global Investments II (U.S.), LP  
   
By: /s/ Robert Munro  
  Robert Munro  
  Chief Compliance Officer  
   
Yorkville Advisors Global, LP  
   
By: Yorkville Advisors Global, LLC  
Its: General Partner  
   
By: /s/ Robert Munro  
  Robert Munro  
  Chief Compliance Officer  
   
Yorkville Advisors Global II, LLC  
   
By: /s/ Robert Munro  
  Robert Munro  
  Chief Compliance Officer  
   
YAII GP, LP  
   
By: YAII GP II, LLC  
Its: General Partner  
   
By: /s/ Robert Munro  
  Robert Munro  
  Chief Compliance Officer  

 

 

 

 

YAII GP II, LLC  
   
By: /s/ Robert Munro  
  Robert Munro  
  Chief Compliance Officer  

 

SC-Sigma Global Partners, LP  
   
By: /s/ Robert Munro  
  Robert Munro  
  Chief Compliance Officer  

 

 

 

Get the next $ALVO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALVO

DatePrice TargetRatingAnalyst
2/14/2025$18.00Buy
UBS
1/29/2024$10.00 → $17.00Equal Weight → Overweight
Barclays
10/20/2023$5.00 → $10.00Sell → Neutral
Citigroup
9/21/2023$10.00Equal Weight
Barclays
9/7/2022$10.00Equal-Weight
Morgan Stanley
9/6/2022$12.00 → $5.00Buy → Sell
Citigroup
More analyst ratings

$ALVO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

    REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently a director and highly ranked equities analyst at Barclays, covering US specialty pharma and with Alvotech in his portfolio. He served previously

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Alvotech Reports Record Results for 2024 and Provides Business Update

    Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3 million compared to negative $291 million in 2023Submissions in major global markets were made in 2024 for three new proposed biosimilars. All applications have been subsequently accepted by the relevant regulatory authorities.Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm GMT). REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

    REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC ("Kashiv"), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted a marketing application for AVT23, a proposed biosimilar to Xolair® (omalizumab), a biologic indicated for trea

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALVO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ALVO
SEC Filings

See more

$ALVO
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALVO
Leadership Updates

Live Leadership Updates

See more
  • Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

    REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently a director and highly ranked equities analyst at Barclays, covering US specialty pharma and with Alvotech in his portfolio. He served previously

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

    REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB's ("Xbrane") R&D operations and a biosimilar candidate (the "Acquisition"), further expanding Alvotech's development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane's R&D operations based in Campus Solna, at the Karolinska Institute outside Stockholm, Sweden, as well as the biosimilar candidate XB003, referencing Cimzia® (certolizumab pegol). Xbrane retains other

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Alvotech Appoints Interim Chief Quality Officer

    REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer. Christina succeeds Sandra Casaca, who is leaving the company as a part of other organizational changes. Christina Siniscalchi has for over ten years served in senior quality positions for Alvogen and its manufacturing site in Norwich, NY, most recently as Alvogen's Chief Quality Officer. "We thank Sandra for her valuable contribution to Alvotech, as she successfully steered ou

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALVO
Financials

Live finance-specific insights

See more
  • Alvotech Reports Record Results for 2024 and Provides Business Update

    Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3 million compared to negative $291 million in 2023Submissions in major global markets were made in 2024 for three new proposed biosimilars. All applications have been subsequently accepted by the relevant regulatory authorities.Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm GMT). REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Alvotech Reports Financial Results for the First Nine Months of 2024

    Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine months of 2024 increased over four-fold compared to the same period last year, to $128 million, with Q3 product revenues contributing $62 millionLicense and other revenues for the first nine months of 2024 increased by $203 from the same period last year, to $211 million, with Q3 license and other revenues contributing $41 millionAdjusted EBITDA was $87 million in the first nine months of 2024, compared to negative ($225) million for the same period last year, with Q3 adjusted EBITDA contributi

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

    REYKJAVIK, Iceland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of the year ended September 30, 2024, after U.S. markets close on Wednesday, November 13, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Thursday November 14, 2024, at 8:00 am ET (13:00 GMT).   Live audio of the conference call will also be webcast and available to members of the news media, investors, and the general public. Access information is posted on Alvotech's

    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALVO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more